Thermalsole und Schwefelbad Bentheim GmbH — Clinical Trial Site

102 Registered trials

36 Currently recruiting

Organisation

Thermalsole und Schwefelbad Bentheim GmbH

Location

Bad Bentheim, Germany

Identifier

ORG-100041599

Address

Am Bade 1, 48455, Germany

Departments

#40740: Dermatology
#7214;Dermatologie
2151: Klinisches Studienzentrum
2201:Dermatologie
40740:Dermatology
43001: Fachklinik Bad Bentheim Klinisches Studienzentrum
5252: Fachklinik Bad Bentheim Klinisches Studienzentrum
6021: Dermatologie
9195: Dermatologie
Abteilung für Dermatologie
Clinical Study Center
Clinical Trial Center
Department Dermatologie
Department of Dermatology
Dept. of Dermatology
Dept. of. Dermatology
Dermatologie
Dermatologie – Fachklinik Bad Bentheim
Dermatologische Studienambulanz
Dermatology
Dermatology Department
DEU02816: Klinisches Studienzentrum
Fachabteilung Dermatologie
Fachbereich Dermatologie und Allergologie
Fachklinik Bad Bentheim
Fachklinik Bad Bentheim – Dermatologie
Fachklinik Bad Bentheim , Klinisches Studienzentrum
Fachklinik Bad Bentheim Abteilung für Dermatologie
Fachklinik Bad Bentheim Abteilung für Rheumatologie
Fachklinik Bad Bentheim Fachbereich Dermatologie
Fachklinik Bad Bentheim Klinisches Studienzentrum
Fachklinik Bad Bentheim, Klinisches Studienzentrum
Klinik fuer Dermatologie
Klinik fuer Dermatologie und Allergologie
Klinik fur Dermatologie
Klinisches Studienzentrum
Klinisches Studienzentrum Am Bade 1
N/A
NA
Practice
Specialized clinic Bad Bentheim Department of Dermatology
Thermalsole- und Schwefelbad Bentheim GmbH
Tsianakas "Specialized clinic Bad Bentheim Department of Dermatology"

Clinical trials at this site (102)

Search interface

A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513210-36-00 Chronic Spontaneous Urticaria 5 2025-04-04
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended

2023-509239-19-00 Active Psoriatic Arthritis 5 2025-04-03
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Ended

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended

2024-510730-40-00 Hidradenitis Suppurativa 5 2024-12-12
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Ended

2024-510753-10-00 Prurigo Nodularis 5 2024-11-01
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
Efficacy and safety of oral minoxidil in women with hormone-imbalanced hair loss Ended

2023-503383-17-01 Female androgenetic alopecia 5 2024-10-10
A Study to Evaluate the Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Ended

2024-511260-84-00 Atopic Dermatitis 4 2024-09-03
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended

2023-505061-82-01 Alopecia Areata 5 2024-06-17
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV… Ended

2023-507456-69-00 Atopic Dermatitis 4 2024-04-25
Selective Treatment of Oral Povorcitinib in Vitiligo Study 2 (STOP-V2) Ended

2023-506011-18-00 Vitiligo 5 2024-04-17
A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended

2023-506195-27-00 non-segmental vitiligo 5 2024-04-05
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co… Ended

2022-502161-19-00 Chronic Spontaneous Urticaria 5 2024-03-12
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505120-59-00 Moderate to Severe Plaque Psoriasis 5 2023-12-19
Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Ended

2023-503661-28-00 Hidradenitis Suppurativa 5 2023-10-26
Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate… Ended

2022-502188-39-00 Dermatitis atopic 4 2023-09-27
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) Ended

2022-502700-78-00 Alopecia areata (AA) 5 2023-09-01
A Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cut… Ended

2023-505634-94-00 Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneo 10 2023-02-02
A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Ev… Ended

2024-514394-22-00 Actinic Keratosis 6 2022-10-24
A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended

2024-514502-31-00 Prurigo Nodularis 5 2021-01-11
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
EffisayilTM ON: A study to test long-term treatment with spesolimab in people with generalized pustular psoriasis who took part in a previou… Ended

2023-509216-28-00 Generalized Pustular Psoriasis 4 2019-05-27
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of… Ended

2024-517814-13-00 Moderate to Severe Atopic Dermatitis 4 2025-04-30